Journal
INTERNIST
Volume 51, Issue 9, Pages 1136-+Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00108-010-2599-0
Keywords
Thrombotic microangiopathies; Thrombocytopenia; von Willebrand factor; Plasmapheresis; Rituximab
Categories
Ask authors/readers for more resources
Thrombotic-thrombocytopenic purpura (TIP) is a microangiopathic disorder characterized by multiple von Willebrand-Factor (vWF) rich microthrombi affecting the arterioles and capillary vessels of several organs. Ultra large von Willebrand multimers cause the blood clotting process by linking to platelets due to a lack of a plasma metalloprotease named ADAMTS13. Deficiency of this vWF-cleaving enzyme is caused by an inborn mutation in the gene coding or, more often, by acquired autoantibodies that inhibit ADAMTS13. TTP is a life-threatening disease which requires urgent admission to a hematological centre. Plasmapheresis therapy should be started immediately when diagnosis of primary TIP is likely. Patients typically present with schistozytes, hemolysis, thrombocytopenia and neurological abnormalities such as headache, focal deficits or coma. The monoclonal CD20 antibody rituximab targets ADAMTS13 antibody production and has the potential to be an effective therapy for relapsed UP or initial treatment to shorten duration of plasma exchange.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available